PLS Group share price climbs after close as investors line up for Feb 19 results

February 16, 2026
PLS Group share price climbs after close as investors line up for Feb 19 results

Sydney, February 16, 2026, 17:33 AEDT — Trading after the bell.

  • PLS Group finished 1.9% higher at A$4.31, shaking off a choppy opening for lithium stocks this week.
  • The ASX-listed lithium producer will deliver its FY26 interim results on Feb. 19.
  • Earnings season is pulling broker models and lithium pricing assumptions back into the spotlight.

PLS Group Ltd finished Monday at A$4.31, gaining 1.9%. The stock saw a session range from A$4.11 to A$4.34.

This one’s notable: PLS is due to report interim results on Thursday, Feb. 19, followed by an investor call and webcast that morning. The company touts itself as a leading lithium materials supplier out of Australia’s Pilgangoora hard-rock site, and it’s got a chemicals JV with POSCO in South Korea.

Across the sector, brokers are reworking their numbers. In its latest weekly broker-tracker, Macquarie bumped its 2026 lithium price outlook up by 95%, putting the spotlight on earnings hits for lithium miners like PLS Group, Liontown Resources, and IGO.

PLS has turned to contract terms to keep cash coming in. Just last week, the company locked in a two-year binding offtake with China’s Canmax, covering 150,000 tonnes a year of spodumene concentrate. There’s a floor price—US$1,000 a tonne, based on SC6, which is about 6% lithium oxide. Canmax is also putting up a US$100 million unsecured prepayment, interest-free, to be repaid as shipments go out. CEO Dale Henderson described the interest-free prepayment and built-in floor price as clear signs of Canmax’s “strong commercial confidence” in PLS’ product and track record. ASX Announcements

Smaller lithium stocks caught a bid as well. Liontown climbed 2.7%, Core Lithium picked up 5.1% for the session, and IGO nudged higher.

The checklist for investors isn’t complicated: realised prices, unit costs, cash, sales volumes. But those details don’t show up until the report drops, so nothing’s certain yet. Commentary on spodumene market conditions and contract pricing—also on the radar.

But there’s a hitch. Lithium’s still driven by momentum, so swings in earnings can just as easily reverse. Miss on price or cost targets, and shares can slip fast—there’s no guarantee every tonne will fetch a minimum price.

Stock Market Today

  • Australia Aspirin Market 2026-2035: Growth in Low-Dose Cardiovascular Segment amid Import Dependency
    May 23, 2026, 11:25 AM EDT. The Australia aspirin market is evolving, with low-dose (81 mg) formulations for cardiovascular prevention driving volume growth to 40-45% of unit sales by 2026. Private-label aspirin captures 25-30% of retail volume, pressuring branded producers amid a 50-60% price gap. The market depends on imports for over 90% of acetylsalicylic acid active pharmaceutical ingredient (API), mainly from China and India, exposing it to supply and cost volatility with input prices up 12-18% in 18 months. Aging demographics boost demand for prophylactic aspirin at 3-5% annual growth, outpacing traditional pain relief. Consumer trends favor coated and combination tablets now 20% of revenues. Online sales channels are expanding, making up 12-15% of volume. Challenges include regulatory costs, API price swings, stockouts, and retail consolidation squeezing supplier margins and innovation.